Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
- PMID: 6136413
- DOI: 10.1007/BF00607090
Contribution of the genetic status of oxidative metabolism to variability in the plasma concentrations of beta-adrenoceptor blocking agents
Abstract
The oxidative metabolism of bufuralol is under the same genetic control as that of debrisoquine and sparteine. 154 fasting volunteers received a 30 mg tablet of bufuralol and a blood sample was taken 3 h later. In poor metabolizers (8% of the sample) the plasma bufuralol concentrations were very high and the metabolite concentrations were low. The genetic oxidative status is a major source of interindividual variation in the plasma concentration of drugs that undergo oxidative metabolism.
Similar articles
-
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.Eur J Clin Pharmacol. 1985;28(3):317-20. doi: 10.1007/BF00543330. Eur J Clin Pharmacol. 1985. PMID: 2861095
-
[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].Schweiz Med Wochenschr. 1983 Feb 26;113(8):295-7. Schweiz Med Wochenschr. 1983. PMID: 6133350 French.
-
The genetic control of bufuralol metabolism in man.Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73-7. doi: 10.1007/BF03189547. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6121708
-
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001. Clin Pharmacokinet. 1986. PMID: 2868819 Review.
-
The genetic control of drug oxidation in the liver.Int J Clin Pharmacol Res. 1983;3(6):421-5. Int J Clin Pharmacol Res. 1983. PMID: 6147316 Review.
Cited by
-
Ethnic differences in drug disposition and responsiveness.Clin Pharmacokinet. 1991 May;20(5):350-73. doi: 10.2165/00003088-199120050-00002. Clin Pharmacokinet. 1991. PMID: 1879095 Review.
-
Variability of plasma drug concentrations: some observations.Eur J Clin Pharmacol. 1983;25(4):569-70. doi: 10.1007/BF00542131. Eur J Clin Pharmacol. 1983. PMID: 6653653 No abstract available.
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
Oxidation phenotype and the metabolism and action of beta-blockers.Klin Wochenschr. 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972. Klin Wochenschr. 1985. PMID: 2860267 Review.
-
Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).Eur J Clin Pharmacol. 1993;45(3):261-4. doi: 10.1007/BF00315393. Eur J Clin Pharmacol. 1993. PMID: 8276051
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources